Future treatment: Inhibition of latent infection

Infectious Diseases in Clinical Practice

Volumn 6, Issue SUPPL. 1, 1997, Pages

  Woolley, Paul ^a  

^a WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PENCICLOVIR; VALACICLOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; DRUG EFFICACY; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; REVIEW;

EID: 0030723028     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199709001-00005     Document Type: Review

References (15)

1. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
2. Fife KH, International Valaciclovir HSV Study Group. Valaciclovir or acyclovir for the treatment of first episode genital herpes [abstract H11] Antiviral Res 1995;35:181.
3. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA 1996;276:44-9.
4. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. Genitourin Med 1997;73:110-6.
5. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995; 123:89-96.
6. Field HJ, Bell SE, Elion GB, Nash AA, Wildy P. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother 1979;15:554-61.
7. Eamshaw DL, Bacon TH, Darlison SJ, Edmonds K. Perkins RW, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36.2747-57.
8. Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989,33:223-9.
9. Vere Hodge RA, Cheng YC. The mode of action of penciclovir. Antiviral Chem Chemother 1993;4:13-24.
10. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-methylbut-1-yl)guanine (BRL-39123) in cell culture. Antimicrob Agents Chemother 1987;31:1238-42.
11. Field HJ, Thackray AM. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 1995a;6:210-6.
12. Field HJ, Tewari D, Sutton D, Thackray AM. Companson of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995b;39:1114-9.
13. Thackray AM, Field HJ Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob Agents Chemother 1996a;40:846-51.
14. Thackray AM, Field HJ. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis 1996;173:291-9.
15. Ahmed A, Woolley PD. Companson of famciclovir and acyclovir in first episodes of genital herpes: possible effect on latency. In: Proceedings of European Conference on Herpes viruses; 1996; Paris, France.